tiprankstipranks
Trending News
More News >

MIRA Pharmaceuticals Announces Promising Preclinical Results for Mira-55

Story Highlights
MIRA Pharmaceuticals Announces Promising Preclinical Results for Mira-55

Don’t Miss TipRanks’ Half-Year Sale

MIRA Pharmaceuticals, Inc. ( (MIRA) ) has shared an announcement.

On July 2, 2025, MIRA Pharmaceuticals announced promising preclinical results for Mira-55, a non-psychoactive marijuana analog, which showed morphine-comparable pain relief in animal models without opioid risks. The drug’s potential is bolstered by its non-classification as a controlled substance by the DEA, facilitating its clinical development. Additionally, MIRA is advancing its acquisition of SKNY Pharmaceuticals, with SKNY-1 showing significant potential in treating obesity and nicotine addiction. The SEC has approved the merger proxy, allowing MIRA to proceed with the acquisition, further strengthening its market position.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing non-opioid pain relief solutions. The company is known for its innovative drug candidates like Mira-55, a non-psychoactive marijuana analog, and Ketamir-2, both targeting large and underserved pain markets.

Average Trading Volume: 1,263,792

Technical Sentiment Signal: Hold

For detailed information about MIRA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1